Investigational Drug Information for Radotinib
✉ Email this page to a colleague
What is the drug development status for Radotinib?
Radotinib is an investigational drug.
There have been 7 clinical trials for Radotinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 28th 2018.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Il-Yang Pharm. Co., Ltd., Asan Medical Center, and Ulsan University Hospital.
Summary for Radotinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 238 |
| WIPO Patent Applications | 339 |
| Japanese Patent Applications | 57 |
| Clinical Trial Progress | Phase 3 (2018-12-28) |
| Vendors | 49 |
Recent Clinical Trials for Radotinib
| Title | Sponsor | Phase |
|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Il-Yang Pharm. Co., Ltd. | Phase 2 |
| Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | Il-Yang Pharm. Co., Ltd. | Phase 3 |
| A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | Il-Yang Pharm. Co., Ltd. | Phase 3 |
Clinical Trial Summary for Radotinib
Top disease conditions for Radotinib
Top clinical trial sponsors for Radotinib
US Patents for Radotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
